Evidence map›Paper›PMID 39415147›Full record

ArticleBMC cancer2024

Cell-cycle phase progression analysis identifies three unique phenotypes in soft tissue sarcoma.

Mark M Cullen, Alexander L Lazarides, Patricia D Pittman, Etienne M Flamant, Kathryn L Stoeber, Kai Stoeber, Julia D Visguass, Brian E Brigman, Richard F Riedel, Diana M Cardona and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mark M CullenDepartment of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA. mark.cullen@duke.edu.
Alexander L LazaridesDepartment of Orthopaedic Surgery, Moffitt Cancer Center, Tampa, FL, USA.
Patricia D PittmanDepartment of Neuropathology, Duke University Health System, Durham, NC, USA.
Etienne M FlamantDepartment of Orthopaedic Surgery, University of Illinois, Chicago, IL, USA.
Kathryn L StoeberLucy Cavendish College, Cambridge University, Cambridge, UK.
Kai StoeberDepartment of Pathology and Cancer Institute, University College London, London, UK.
Julia D VisguassDepartment of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA.
Brian E BrigmanDepartment of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA.
Richard F RiedelDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Diana M CardonaDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.
Jason A SomarelliDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
William C EwardDepartment of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLoddo et al. (Br J Cancer 100:959-70, 2009) established the prognostic significance of cell cycle markers and "Cell-Cycle Phenotypes" in breast carcinoma. This study aims to 1) identify prognostic cell-cycle markers in sarcoma, and 2) assess the prognostic potential of specific cell-cycle phenotypes in sarcoma.

methodsTissue samples from 128 soft tissue sarcomas were stained for four cell cycle-specific markers: Mcm2, Geminin, Plk1, and H3S10ph. Only primary soft tissue tumors (liposarcoma, leiomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma) were included in the analysis. Any tumor coming from a recurrent or metastatic lesion were excluded from the analysis. Three cell-cycle phenotypes (I, II, III) were derived from marker expression patterns. Prognostic significance was evaluated in a subset of primary soft tissue sarcomas using Cox regression for survival analysis.

resultsCompared to phenotype I, the phenotype III tumors had a decreased 5-year overall survival (HR 6.81 [2.36-19.61]; p =  < 0.001), 5-year disease-free survival (HR 1.07 (1.02-1.18); p = 0.004), and 5-year metastasis-free survival (HR 4.34 [1.58-11.93]; p = 0.004). High expression of Plk1 was associated with decreased 5-year overall survival (HR: 4.04 CI [1.21-6.67; p = 0.02) and 5-year metastasis-free survival (HR: 2.91 CI [1.15-7.37]; p = 0.03). Geminin was also found to have a decreased 5-year overall survival (HR:2.84 CI [1.21-6.67]; p = 0.02). No statistical difference in prognostication were noted between phenotypes and the AJCC system.

conclusionsWe identified three unique sarcoma cell cycle phenotypes that have prognostic significance. This performs similarly to the AJCC staging system.

Indexed as

Cell Cycle ProteinsPhenotypeSarcomaAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCell CycleFemaleHumansMaleMiddle AgedPolo-Like Kinase 1PrognosisYoung AdultBiomarkers, TumorCell Cycle ProteinsPolo-Like Kinase 1Cell-cyclePhenotypesPrognosisSarcoma

Identifiers

PMID39415147
PMCPMC11483990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.